(18)F-FDG PET/CT versus anatomic imaging for evaluating disease extent and clinical trial eligibility in Erdheim-Chester disease: Results from 50 patients in a registry study Journal Article
| Authors: | Kirchner, J.; Hatzoglou, V.; Buthorn, J. B.; Bossert, D.; Sigler, A. M.; Reiner, A. S.; Ulaner, G. A.; Diamond, E. L. |
| Article Title: | (18)F-FDG PET/CT versus anatomic imaging for evaluating disease extent and clinical trial eligibility in Erdheim-Chester disease: Results from 50 patients in a registry study |
| Abstract: | Objectives: The aim of this study was to [1] characterize distribution of Erdheim-Chester Disease (ECD) by 18F-FDG PET/CT and [2] determine the utility of metabolic (18F-FDG PET/CT) imaging versus anatomic imaging (CT or MRI) in evaluating ECD patients for clinical trial eligibility. Methods: 18F-FDG PET/CT and corresponding CT or MRI studies for ECD patients enrolled in a prospective registry study were reviewed. Sites of disease were classified as [1] detectable by 18F-FDG PET only, CT/MRI only, or both and as [2] measurable by modified PERCIST (mPERCIST) only, RECIST only, or both. Descriptive analysis was performed and paired t test for between-group comparisons. Results: Fifty patients were included (mean age 51.5 years; range 18–70 years). Three hundred thirty-three disease sites were detected among all imaging modalities, 188 (56%) by both 18F-FDG PET and CT/MRI, 67 (20%) by 18F-FDG PET only, 75 (23%) by MRI brain only, and 3 (1%) by CT only. Of 178 disease sites measurable by mPERCIST or RECIST, 40 (22%) were measurable by both criteria, 136 (76%) by mPERCIST only, and 2 (1%) by RECIST only. On the patient level, 17 (34%) had mPERCIST and RECIST measurable disease, 30 (60%) had mPERCIST measurable disease only, and 0 had RECIST measurable disease only (p < 0.0001). Conclusion: Compared with anatomic imaging, 18F-FDG PET/CT augments evaluation of disease extent in ECD and increases identification of disease sites measurable by formal response criteria and therefore eligibility for clinical trials. Complementary organ-specific anatomic imaging offers the capacity to characterize sites of disease in greater anatomic detail. Trial registration: ClinicalTrials.gov Identifier: NCT03329274 © 2020, The Author(s). |
| Keywords: | recist; 18f-fdg pet/ct; erdheim-chester disease; ecd; modified percist; trial eligibility |
| Journal Title: | European Journal of Nuclear Medicine and Molecular Imaging |
| Volume: | 48 |
| Issue: | 4 |
| ISSN: | 1619-7070 |
| Publisher: | Springer |
| Date Published: | 2021-04-01 |
| Start Page: | 1154 |
| End Page: | 1165 |
| Language: | English |
| DOI: | 10.1007/s00259-020-05047-8 |
| PUBMED: | 33057928 |
| PROVIDER: | scopus |
| PMCID: | PMC8041681 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 3 May 2021 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work